Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventing diabetic nephropathy: an audit.

H P Hansen1, S S Lund, P Rossing

  • 1Steno Diabetes Center, Gentofte, Denmark. hpha@novo.dk

Scandinavian Journal of Clinical and Laboratory Investigation
|October 30, 2001
PubMed
Summary

Angiotensin converting enzyme (ACE) inhibition significantly reduced microalbuminuria progression in type 1 diabetic patients. This treatment strategy lowered the risk of developing diabetic nephropathy, aligning with previous trial findings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimated GFR: Are There Limits to Its Utility?: Monitoring Kidney Function in Type 2 Diabetic Patients with Incipient and Overt Diabetic Nephropathy. Diabetes Care 29: 1024-1030, 2006.

Journal of the American Society of Nephrology : JASN·2023
Same author

Effect of far infrared therapy on arteriovenous fistula maturation, survival and stenosis in hemodialysis patients, a randomized, controlled clinical trial: the FAITH on fistula trial.

BMC nephrology·2021
Same author

CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.

Oncogene·2016
Same author

Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.

Diabetes & metabolism·2016
Same author

ACTH stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia.

Clinical endocrinology·2014
Same author

At least one in three people with Type 2 diabetes mellitus referred to a diabetes centre has symptomatic obstructive sleep apnoea.

Diabetic medicine : a journal of the British Diabetic Association·2014

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Type 1 diabetes with microalbuminuria carries a significant risk of diabetic nephropathy.
  • Previous reports indicate annual increases in urinary albumin excretion rate (AER) and nephropathy development.
  • Antihypertensive treatment, specifically ACE inhibition, is a key consideration for these patients.

Purpose of the Study:

  • To audit the effect of angiotensin converting enzyme (ACE) inhibition on microalbuminuria progression.
  • To assess the impact of ACE inhibition on the development of diabetic nephropathy in type 1 diabetic patients.
  • To evaluate the implementation of international guidelines for ACE inhibitor use in this population.

Main Methods:

  • Consecutive identification of 227 type 1 diabetic patients with persistent microalbuminuria (30-300mg/24h).

Related Experiment Videos

  • Risk stratification into high- and low-risk groups based on AER level and progression rate.
  • Recommendation of ACE inhibitor treatment for high-risk patients according to international guidelines.

    • Main Results:

    • Overall urinary AER significantly declined by 8.3% per year in the study group.
    • The risk for developing diabetic nephropathy during follow-up was 3.5% per year.
    • Glycemic control and blood pressure remained stable throughout the study period.
    • 67% of patients received ACE inhibitor treatment during the study.

    Conclusions:

    • Implementing modified international guidelines for ACE inhibition effectively reduced diabetic nephropathy progression in microalbuminuric type 1 diabetic patients.
    • The observed reduction in nephropathy progression is comparable to results from previous intervention trials.
    • ACE inhibition is a valuable therapeutic strategy for managing microalbuminuria and preventing diabetic nephropathy in type 1 diabetes.